A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma

Name: RRM: Phase 2 trial 2025-523117-28 – HSH
Published: 2026-09-17T12:57:35+00:00

Trial information

Site city	Organisation name	Department name	Name	Email	Telephone number
Alexandroupolis	University General Hospital of Alexandroupolis	Hematology Clinic	Emmanouil Spanoudakis		2551353154
Ioannina	University General Hospital of Ioannina	Department of Hematology, Clinical Studies Office	Eleftheria Hatzimichael		2651099650

Cookie	Duration	Purpose
`eae_consent`	180 days	Remembers your cookie choices.
`wp-wpml_current_language`	Session	Remembers the language of the site you chose.

Cookie	Duration	Purpose
`_ga`	2 years	Distinguishes visitors.
`_ga_*`	2 years	Keeps the state of a visit.